Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer

June 23, 2022 | Hope Rugo, MD, FASCO

Share on:

Hope Rugo, MD, FASCO, reviews safety and efficacy results from the TROPiCS-02 trial and discusses the clinical implications of the data.

onclive rapid readouts logo